Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial

被引：0
作者：
Jieting Tang
Yongfeng Wang
Tao Han
Qing Mao
Jun Cheng
Huiguo Ding
Jia Shang
Qin Zhang
Junqi Niu
Feng Ji
Chengwei Chen
Jidong Jia
Xiangjun Jiang
Nonghua Lv
Yueqiu Gao
Zhenghua Wang
Zhong Wei
Yingxuan Chen
Minde Zeng
Yimin Mao
机构：
[1] Shanghai Jiao Tong University,School of Medicine Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine
[2] Shanghai Institute of Digestive Disease,Beijing Ditan Hospital
[3] Tianjin Third Hospital,Beijing Youan Hospital
[4] Southwest Hospital,The First Affiliated Hospital
[5] Capital Medical University,Beijing Friendship Hospital
[6] Capital Medical University,undefined
[7] Henan Provincial Peoples Hospital,undefined
[8] Shanghai Public Health Clinical Center,undefined
[9] The First Hospital of Jilin University,undefined
[10] Zhejiang University,undefined
[11] 85 Hospital of Peoples Liberation Army,undefined
[12] Capital Medical University,undefined
[13] Qingdao Municipal Hospital,undefined
[14] The First Affiliated Hospital of Nanchang University,undefined
[15] Shanghai Shuguang Hospital,undefined
来源：
BMC Gastroenterology | / 20卷
关键词：
Liver cirrhosis; Cirrhotic patients; Tolvaptan; Ascites;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 179 条
[1]  
Gines P(1987)Compensated cirrhosis: natural history and prognostic factors Hepatology 7 122-128
[2]  
Quintero E(2018)EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis J Hepatol 69 406-460
[3]  
Arroyo V(2017)Diuretic Resistance Am J Kidney Dis 69 136-142
[4]  
Teres J(2003)Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety J Hepatol 39 187-192
[5]  
Bruguera M(2016)Evidence-based clinical practice guidelines for liver cirrhosis 2015 J Gastroenterol 51 629-650
[6]  
Rimola A(1995)Vitamin E therapy of acute CC14-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding Hepatology 22 7-154
[7]  
Hoorn EJ(2018)Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial J Dig Dis 19 144-91
[8]  
Ellison DH(2014)Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial Hepatol Res 44 83-739
[9]  
Santos J(2014)Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy Hepatol Res 44 735-470
[10]  
Planas R(2014)Tolvaptan for the treatment of liver cirrhosis oedema Expert Rev Gastroenterol Hepatol 8 461-21
12345678910